Odedra K, Ferro A
Faculty of Medicine and Cardiovascular Division, GKT School of Medicine, King's College London, London, UK.
Int J Clin Pract. 2006 Jul;60(7):835-46. doi: 10.1111/j.1742-1241.2006.00996.x.
Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase. The pathophysiology of heart failure is multi-factorial but recent studies suggest that aldosterone plays an important and independent role in its progression. Emerging evidence now suggests that aldosterone exerts renal-independent effects. It binds to its mineralocorticoid receptor to produce direct effects on the myocardium and vasculature, leading to damaging processes such as hypertrophy, necrosis, fibrosis and endothelial dysfunction, factors known to contribute to the pathophysiology of heart failure. Mineralocorticoid receptor antagonists have thus emerged as a new paradigm for the treatment of heart failure. The benefits of these agents on both morbidity and mortality when used in patients with chronic symptomatic heart failure have been demonstrated by recent trials.
心力衰竭是心血管疾病发病和死亡的主要原因,且其发病率正在上升。心力衰竭的病理生理学是多因素的,但最近的研究表明,醛固酮在其进展过程中起着重要且独立的作用。新出现的证据表明,醛固酮具有非依赖于肾脏的作用。它与盐皮质激素受体结合,对心肌和血管产生直接影响,导致诸如肥大、坏死、纤维化和内皮功能障碍等损害过程,这些因素已知会导致心力衰竭的病理生理过程。因此,盐皮质激素受体拮抗剂已成为治疗心力衰竭的一种新范例。近期试验已证明,这些药物用于慢性症状性心力衰竭患者时,对发病率和死亡率均有益处。